Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Yueh Sheng Chen; Weng Tein Gi; Tin Yun Liao; Meng Tse Gabriel Lee; Si Huei Lee; Wan Ting Hsu; Shy Shin Chang; Chien Chang Lee

doi:10.2217/bmm.15.121

Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Yueh Sheng Chen, Weng Tein Gi, Tin Yun Liao, Meng Tse Gabriel Lee, Si Huei Lee, Wan Ting Hsu, Shy Shin Chang, Chien Chang Lee

Research output: Contribution to journal › Review article › peer-review

26 Citations (Scopus)

Abstract

Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.

Original language	English
Pages (from-to)	329-342
Number of pages	14
Journal	Biomarkers in Medicine
Volume	10
Issue number	3
DOIs	https://doi.org/10.2217/bmm.15.121
Publication status	Published - Mar 2016
Externally published	Yes

Keywords

Galectin-3
heart failure
prognostic marker

ASJC Scopus subject areas

Drug Discovery
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.2217/bmm.15.121

Cite this

@article{c17942eed47e4472812d6f2894244857,

title = "Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis",

abstract = "Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.",

keywords = "Galectin-3, heart failure, prognostic marker",

author = "Chen, {Yueh Sheng} and Gi, {Weng Tein} and Liao, {Tin Yun} and Lee, {Meng Tse Gabriel} and Lee, {Si Huei} and Hsu, {Wan Ting} and Chang, {Shy Shin} and Lee, {Chien Chang}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = mar,

doi = "10.2217/bmm.15.121",

language = "English",

volume = "10",

pages = "329--342",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Using the galectin-3 test to predict mortality in heart failure patients

T2 - A systematic review and meta-analysis

AU - Chen, Yueh Sheng

AU - Gi, Weng Tein

AU - Liao, Tin Yun

AU - Lee, Meng Tse Gabriel

AU - Lee, Si Huei

AU - Hsu, Wan Ting

AU - Chang, Shy Shin

AU - Lee, Chien Chang

PY - 2016/3

Y1 - 2016/3

N2 - Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.

AB - Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.

KW - Galectin-3

KW - heart failure

KW - prognostic marker

UR - http://www.scopus.com/inward/record.url?scp=84959463598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959463598&partnerID=8YFLogxK

U2 - 10.2217/bmm.15.121

DO - 10.2217/bmm.15.121

M3 - Review article

C2 - 26860036

AN - SCOPUS:84959463598

SN - 1752-0363

VL - 10

SP - 329

EP - 342

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 3

ER -

Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this